Fate Therapeutics gets RMAT status from FDA for Lupus treatment
Source: SeekingAlpha
2025-04-14 11:34:06 ET
More on Fate Therapeutics
- Fate Therapeutics Has Promising Off-The-Shelf Cell Therapies While Looking Cheap
- Seeking Alpha’s Quant Rating on Fate Therapeutics
- Historical earnings data for Fate Therapeutics
- Financial information for Fate Therapeutics
Read the full article on Seeking Alpha
For further details see:
Fate Therapeutics gets RMAT status from FDA for Lupus treatment
Fate Therapeutics Inc.
NASDAQ: FATE
FATE Trading
-5.02% G/L:
$1.135 Last:
521,183 Volume:
$1.18 Open:
FATE Latest News
March 04, 2026 04:05:00 pm
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
March 03, 2026 04:05:00 pm
Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference
March 03, 2026 10:02:00 am
Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them
February 26, 2026 09:00:00 am
Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
FATE Stock Data
$128,041,041
108,996,378
1.54%
45
N/A
Biotechnology & Life Sciences
Healthcare
US
San Diego
